A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers

NCT02429232 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Osteoporosis
Diabetes Mellitus

Interventions

DRUG: Pioglitazone
DRUG: Linagliptin

Sponsor

National Taiwan University Hospital